{"product_id":"granulox-topical-haemoglobin-spray","title":"360001 Granulox Topical Haemoglobin Spray 12ml","description":"\u003cdiv style=\"background: #f8f9fa; border-left: 4px solid #0057a8; padding: 12px 16px; margin-bottom: 20px;\" id=\"ai-summary\"\u003e\n\u003cstrong\u003eClinical Summary:\u003c\/strong\u003e Granulox® (REF 360001) is a topical haemoglobin spray manufactured by Mölnlycke Health Care AB, classified as a Class III CE-marked medical device under EU MDR 2017\/745, indicated as adjunct therapy for chronic hard-to-heal wounds including diabetic foot ulcers, venous and arterial leg ulcers, pressure injuries, and post-surgical wounds. The spray delivers highly purified porcine haemoglobin directly to the wound bed, where it binds ambient oxygen and releases it via facilitated diffusion into hypoxic wound tissue, correcting localised oxygen deficits that impede cellular proliferation and granulation. A 2018 meta-analysis of pooled cohort data (PMID: 29988544) demonstrated statistically significant improvements in healing rates across diabetic foot ulcers (p=0.01), venous leg ulcers (p=0.04), traumatic wounds (p\u0026lt;0.001), burns (p=0.02), and post-surgical wounds (p=0.001) when Granulox® was added to standard wound care.\u003c\/div\u003e\n\u003ch2\u003eProduct Overview\u003c\/h2\u003e\n\u003cp\u003eGranulox® Topical Haemoglobin Spray is an oxygenating adjunct therapy developed to address tissue hypoxia in chronic, stalled wounds. Wound hypoxia — defined as a partial pressure of oxygen below 20 mmHg in the wound bed — suppresses fibroblast proliferation, keratinocyte migration, collagen synthesis, and neutrophil bactericidal activity, resulting in non-healing or slowly healing wounds. Granulox® corrects this deficit by delivering a thin film of highly purified porcine haemoglobin onto the wound surface; the haemoglobin then binds oxygen from ambient air and releases it via simplified (facilitated) diffusion into the underlying wound tissue, mimicking the physiological role of erythrocyte haemoglobin in oxygen transport.\u003c\/p\u003e\n\u003cp\u003eEMIS Singapore supplies Granulox® 12 ml (REF 360001) for clinical procurement by hospitals, specialist wound care clinics, community health teams, and home care providers across Singapore. The product is compatible with all breathable, non-occlusive secondary dressings and is applied before dressing placement. The 12 ml bottle delivers approximately 200 spray actuations, sufficient for multiple dressing changes over a standard 13-week treatment course. A Singapore-specific case series published in the \u003cem\u003eInternational Wound Journal\u003c\/em\u003e (PMID: 32349571) documented complete or near-complete healing in patients with refractory venous leg ulcers and diabetic foot ulcers following adjunct use of Granulox®.\u003c\/p\u003e\n\u003ch2\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable style=\"width: 100%; border-collapse: collapse; font-size: 14px;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold; width: 35%;\"\u003eManufacturer\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eMölnlycke Health Care AB, Gothenburg, Sweden\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eProduct Name\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eGranulox® Topical Haemoglobin Spray\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eREF \/ Product Code\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003e360001\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eActive Ingredient\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eHighly purified porcine haemoglobin (spray solution)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eVolume per Bottle\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003e12 ml (~200 actuations)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eDevice Classification\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eClass III Medical Device — EU MDR 2017\/745 CE-marked\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eRegulatory Clearance\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eCE Mark (EU MDR 2017\/745); HSA-registered medical device, Singapore\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eApplication Method\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eSpray 1–2 actuations per 10 cm² wound area onto wound bed; cover with breathable non-occlusive secondary dressing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eDosing Frequency\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eMinimum twice weekly; at each dressing change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eWound Compatibility\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eModerate to heavily exuding chronic wounds; not for occlusive dressing use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"background: #f0f4f8;\"\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eStorage\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eStore below 25°C; protect from direct sunlight; do not freeze\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd; font-weight: bold;\"\u003eQuality Standard\u003c\/td\u003e\n\u003ctd style=\"padding: 8px 12px; border: 1px solid #ddd;\"\u003eManufactured under ISO 13485:2016 quality management system\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2\u003eClinical Indications\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eDiabetic foot ulcers (DFU):\u003c\/strong\u003e Adjunct to standard offloading, debridement, and moist wound care in neuropathic or neuroischaemic DFUs with stalled healing; aligned with IWGDF 2023 guidance on topical oxygen therapy.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eVenous leg ulcers (VLU):\u003c\/strong\u003e Used alongside compression bandaging per Singapore MOH clinical practice guidelines; a randomised controlled trial demonstrated 53% wound size reduction vs. 21% increase in standard care at 13 weeks.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eArterial and mixed-aetiology leg ulcers:\u003c\/strong\u003e Applied as adjunct where underlying ischaemia limits tissue oxygen delivery; requires concurrent vascular assessment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePressure injuries (Stage III–IV):\u003c\/strong\u003e Indicated for hypoxic pressure injuries in immobile or palliative patients with recalcitrant wound beds; applied prior to foam or hydrofibre secondary dressings.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePost-surgical dehisced wounds:\u003c\/strong\u003e Accelerates secondary intention healing in surgical site dehiscence; pooled cohort evidence (PMID: 29988544, p=0.001) supports use in this wound category.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBurn wounds (partial thickness):\u003c\/strong\u003e Adjunct to moist wound care in partial-thickness burns to support re-epithelialisation; clinical benefit demonstrated in pooled meta-analysis data.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is the mechanism by which Granulox® delivers oxygen to wound tissue?\u003c\/h3\u003e\n\u003cp\u003eGranulox® contains highly purified porcine haemoglobin suspended in a spray solution. When applied to the wound bed, the haemoglobin film binds molecular oxygen from ambient air at the wound surface (partial pressure ~21 kPa) and releases it by facilitated diffusion into the hypoxic wound tissue below (partial pressure typically \u0026lt;3 kPa in chronic wounds). This mimics the physiological oxygen-carrying function of red blood cells without requiring a vascular delivery route, making it effective in ischaemic or poorly vascularised wound beds where systemic oxygen delivery is insufficient.\u003c\/p\u003e\n\u003ch3\u003eHow does Granulox® interact with different secondary wound dressings?\u003c\/h3\u003e\n\u003cp\u003eGranulox® must be used with breathable, non-occlusive secondary dressings that allow ambient air to reach the haemoglobin film. Compatible dressings include foam dressings (e.g., Mepilex®, Allevyn®), alginate dressings, hydrocolloid dressings with perforations, and non-woven contact layers. Occlusive film dressings (e.g., transparent adhesive films applied as a sole dressing) should not be used as secondary covers, as they block the oxygen supply required for haemoglobin saturation. Granulox® is applied first, directly onto the wound bed, then covered with the chosen secondary dressing.\u003c\/p\u003e\n\u003ch3\u003eIs Granulox® suitable for infected wounds, and should antimicrobial dressings be used concurrently?\u003c\/h3\u003e\n\u003cp\u003eGranulox® is not classified as an antimicrobial agent and does not replace debridement or antimicrobial dressings in critically colonised or clinically infected wounds. However, by improving wound oxygenation, it supports neutrophil bactericidal activity — neutrophil oxidative burst requires adequate tissue oxygen. In wounds with critical colonisation or local infection, antimicrobial primary dressings (e.g., silver alginate, DACC-coated, or iodine-based) may be used as the primary contact layer before applying Granulox® spray, subject to clinician assessment. Systemic antibiotics for clinical infection should be managed per Singapore MOH antimicrobial stewardship guidelines.\u003c\/p\u003e\n\u003ch3\u003eWhat clinical evidence supports Granulox® use, and are there Singapore-specific data?\u003c\/h3\u003e\n\u003cp\u003eThe evidence base for Granulox® includes multiple retrospective cohort studies and a 2018 pooled meta-analysis (PMID: 29988544) demonstrating significantly improved healing rates across five wound categories when added to standard care. A Singapore-specific case series (PMID: 32349571, published in the \u003cem\u003eInternational Wound Journal\u003c\/em\u003e) documented outcomes in Singapore patients with venous leg ulcers and diabetic foot ulcers, supporting the product's clinical relevance in the local care setting. The International Working Group on the Diabetic Foot (IWGDF) 2023 guidelines include a conditional recommendation to consider topical oxygen as adjunct therapy for DFUs failing standard care.\u003c\/p\u003e\n\u003ch3\u003eHow do Singapore clinics and home care providers procure Granulox® through EMIS?\u003c\/h3\u003e\n\u003cp\u003eEMIS Singapore (emis.asia) supplies Granulox® REF 360001 to hospitals, specialist wound care clinics, polyclinics, community nursing providers, and home care settings islandwide. Procurement is available via direct B2B order through the EMIS website or by contacting our clinical supply team. HSA-registered medical device importation and distribution requirements are fulfilled by EMIS as the licensed distributor. Repeat orders can be arranged on standing order for institutions with ongoing wound care programmes. Delivery is available island-wide with same-day or next-day options for urgent clinical needs.\u003c\/p\u003e\n\n\u003cscript type=\"application\/ld+json\"\u003e\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@type\": \"FAQPage\",\n  \"mainEntity\": [\n    {\n      \"@type\": \"Question\",\n      \"name\": \"What is Granulox Topical Haemoglobin Spray 12ml used for?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox Topical Haemoglobin Spray 12ml by Molnlycke is a advanced wound dressing used for wound management. It is designed to support moist wound healing, manage exudate, and protect the wound bed from contamination. It is commonly used in Singapore hospitals and home care settings for chronic wounds, post-surgical wounds, and ulcers. Always follow the guidance of your wound care nurse or doctor when selecting a dressing.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"How often should Granulox Topical Haemoglobin Spray 12ml be changed?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox Topical Haemoglobin Spray 12ml should generally be changed every 1–7 days depending on wound type and exudate. However, frequency should always be guided by your wound care nurse or clinician based on wound size, exudate level, and signs of infection. Do not leave any dressing in place if it becomes saturated, dislodged, or if the wound shows signs of infection such as increased redness, warmth, or discharge.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Is Granulox Topical Haemoglobin Spray 12ml available without prescription in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Yes, Granulox Topical Haemoglobin Spray 12ml is available for purchase from EMIS+ (emis.asia) without a prescription for general wound care use. For complex or chronic wounds, we strongly recommend consulting a wound care nurse, GP, or specialist at a Singapore hospital such as SGH, NUH, TTSH, or CGH before selecting a dressing. EMIS+ nurses can also provide product guidance — contact us at emis.asia\/pages\/contact.\"\n      }\n    },\n    {\n      \"@type\": \"Question\",\n      \"name\": \"Where can I buy Granulox Topical Haemoglobin Spray 12ml in Singapore?\",\n      \"acceptedAnswer\": {\n        \"@type\": \"Answer\",\n        \"text\": \"Granulox Topical Haemoglobin Spray 12ml is available from EMIS+ at emis.asia, Singapore's nurse-led medical supply store. We offer fast island-wide delivery, competitive pricing, and bulk ordering for healthcare facilities and home care users. Visit emis.asia or contact our team for assistance.\"\n      }\n    }\n  ]\n}\n\u003c\/script\u003e","brand":"Molnlycke","offers":[{"title":"Default Title","offer_id":43302979633230,"sku":"23304909","price":280.0,"currency_code":"SGD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3763\/2846\/files\/97_ba0c5482-bbcd-4b0f-9c99-84b942be594c.png?v=1777431589","url":"https:\/\/www.emis.asia\/zh-tw\/products\/granulox-topical-haemoglobin-spray","provider":"EMIS +","version":"1.0","type":"link"}